Benlysta
PHONETIC PRONUNCIATION: Benlysta
Description
Benlysta, also known as belimumab, is a medication used in the treatment of systemic lupus erythematosus (SLE), a chronic autoimmune disease. It belongs to a class of drugs called monoclonal antibodies which work by targeting and blocking the actions of certain proteins involved in the immune system. Uses Benlysta is used to treat adults with active, autoantibody-positive SLE who are receiving standard therapy. It is not recommended for use in patients with severe active lupus nephritis or in combination with other biologic therapies. Dosage The recommended dosage of Benlysta is based on a patient's weight. It is given as an intravenous infusion once every four weeks. The initial infusion is typically given over a period of 1 hour and 15 minutes, and subsequent infusions can be given over a shorter period of time if the patient tolerates the medication well. Demographic Benlysta is approved for use in adults with active, autoantibody-positive SLE who are receiving standard therapy. It has not been studied in pediatric patients or in patients with severe active lupus nephritis. Side Effects The most common side effects of Benlysta include infusion reactions, fever, nausea, and diarrhea. Other potential side effects include infections, hypersensitivity reactions, depression, and suicidal thoughts. Patients should be monitored for signs of infection, and those with a history of depression should be closely monitored for the emergence of suicidal thoughts. Interactions There are currently no known drug interactions with Benlysta. However, patients should inform their healthcare providers of all medications they are taking before receiving Benlysta. Generic Options Currently, there are no generic versions of Benlysta available. It is only available as a branded medication, and is only administered in a healthcare setting. In conclusion, Benlysta is a medication used to treat adults with active, autoantibody-positive SLE who are receiving standard therapy. It is given as an intravenous infusion once every four weeks and is known to cause some side effects. Patients should inform their healthcare providers of all medications they are taking before receiving Benlysta. Finally, it currently has no generic options available.
Faq for Benlysta
Benlysta (belimumab) is a prescription medication used to treat certain types of autoimmune diseases, specifically systemic lupus erythematosus (SLE) in adults and children who are at least 5 years old.
Benlysta works by targeting a specific protein called B-lymphocyte stimulator (BLyS) that is involved in the activation and growth of B cells, which play a role in the autoimmune response. By blocking BLyS, Benlysta helps to reduce autoantibody production and the activity of B cells, helping to manage symptoms of SLE.
Benlysta can be administered as an intravenous (IV) infusion or as a subcutaneous injection. The IV infusion is typically given by a healthcare professional in a hospital or clinic setting, while the subcutaneous injection can be self-administered at home after proper training.
The common side effects of Benlysta may include nausea, diarrhea, fever, cough, sore throat, stuffy or runny nose, insomnia, muscle or joint pain, and headache. It is important to discuss these side effects with your healthcare provider.
The effects of Benlysta can vary from person to person. Some individuals may start experiencing improvements in their symptoms within a few weeks of starting treatment, while for others, it may take several months. It is important to continue the prescribed treatment as directed by your healthcare provider.
Yes, Benlysta is often used in combination with other medications commonly prescribed for SLE, such as corticosteroids, immunosuppressants, and nonsteroidal anti-inflammatory drugs (NSAIDs). However, it is essential to inform your healthcare provider about all the medications you are taking to ensure safety and potential drug interactions.
The safety of Benlysta in pregnant or breastfeeding women has not been established. It is recommended to discuss with your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding before starting treatment with Benlysta.
The frequency of Benlysta administration depends on whether it is given as an IV infusion or a subcutaneous injection. The IV infusion is typically given once every 4 weeks, while the subcutaneous injection is usually administered once weekly. Note: The above information is for general informational purposes only and should not replace medical advice. It is important to consult with a healthcare professional for personalized advice and information about Benlysta.